CRBP240920P40000
- 0.40
- -0.17-29.82%
Corbus Pharmaceuticals Newsroom
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating
Buy Rating Affirmed for Corbus Pharmaceuticals Amid Promising Outlook for Novel Oral Weight Loss Therapy CRBP-913
Corbus Pharmaceuticals Price Target Maintained With a $82.00/Share by RBC Capital
Corbus Pharmaceuticals Analyst Ratings
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $82
RBC Capital Remains a Buy on Corbus Pharmaceuticals (CRBP)
Mizuho Securities Initiates Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $74
Optimistic Outlook on Corbus Pharmaceuticals' Oncology and Obesity Drug Candidates Supports Buy Rating
Mizuho Initiates Corbus Pharmaceuticals at Outperform With $74 Price Target
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $88
Corbus Pharmaceuticals (CRBP) Initiated With a Buy at RBC Capital
HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $80 Price Target
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $80
Buy Rating for Corbus Pharmaceuticals' CRB-701 Based on Promising Oncology Trial Results and Therapeutic Potential
Wedbush Initiates Corbus Pharmaceuticals at Outperform With $85 Price Target
Wedbush Initiates Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $85
Corbus Pharmaceuticals Analyst Ratings
H.C. Wainwright Initiates Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Announces Target Price $80
Buy Rating Affirmed: Corbus Pharmaceuticals' Promising Drug Pipeline and Growth Potential
Corbus Pharmaceuticals Analyst Ratings